PATENT CLAIM ANALYSIS

Application Number: 15978390
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["424", "135100"]

Abstract:
The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to IL23R-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.

Claim (Index 2):
The method according to  claim 1 , wherein the inflammatory and/or autoimmune disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, juvenile diabetes, autoimmune uveitis, and multiple sclerosis, Parkinson's disease, Alzheimer's disease, and ischemia-reperfusion injury.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 93.0
- Lexical Diversity: 1.42857
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14889225', '15829783', '15604153', '15225107', '15829793']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7234701313859166
- 35 USC 102 Novelty (BERT): 0.6515549107638913
- Combined Prediction Score: 0.7162786093237141
- Mean Citation Score: 362.187456
- Max Citation Score: 680.0639
- Similarity Product: 568.5082653722047

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test